A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (ET743-OVC-3006)

Journal article

Peer reviewed

B.J. Monk, T.J. Herzog, S. Triantos, G. Wang, W.S.W. Shalaby, T. McGowan and R.L. Coleman

Gynecologic oncology, Vol.154, pp.12-13

06/2019

Metrics

5 Record Views

Title: A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (ET743-OVC-3006)
Creators: B.J. Monk - The US Oncology Network
T.J. Herzog - University of Cincinnati
S. Triantos - Janssen
G. Wang - Janssen
W.S.W. Shalaby - Product Innovation and Engineering (United States, Saint James) - LLC
T. McGowan - Janssen
R.L. Coleman - The University of Texas MD Anderson Cancer Center
Publication Details: Gynecologic oncology, Vol.154, pp.12-13
Publisher: Elsevier Inc
Identifiers: 991005969164602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article